KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Net Income - Minority: 2009-2024

Historic Net Income - Minority for Teva Pharmaceutical Industries (TEVA) over the last 15 years, with Dec 2024 value amounting to -$7.0 million.

  • Teva Pharmaceutical Industries' Net Income - Minority rose 98.75% to -$4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.0 million, marking a year-over-year increase of 98.75%. This contributed to the annual value of -$7.0 million for FY2024, which is 98.87% up from last year.
  • As of FY2024, Teva Pharmaceutical Industries' Net Income - Minority stood at -$7.0 million, which was up 98.87% from -$620.0 million recorded in FY2023.
  • Teva Pharmaceutical Industries' 5-year Net Income - Minority high stood at -$7.0 million for FY2024, and its period low was -$1.0 billion during FY2020.
  • In the last 3 years, Teva Pharmaceutical Industries' Net Income - Minority had a median value of -$620.0 million in 2023 and averaged -$473.7 million.
  • Data for Teva Pharmaceutical Industries' Net Income - Minority shows a peak YoY skyrocketed of 98.87% (in 2024) over the last 5 years.
  • Teva Pharmaceutical Industries' Net Income - Minority (Yearly) stood at -$1.0 billion in 2020, then grew by 6.67% to -$966.0 million in 2021, then grew by 17.81% to -$794.0 million in 2022, then increased by 21.91% to -$620.0 million in 2023, then skyrocketed by 98.87% to -$7.0 million in 2024.